These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11437695)

  • 1. Immunological aspects of alzheimer's disease: therapeutic implications.
    Hoozemans JJ; Rozemuller AJ; Veerhuis R; Eikelenboom P
    BioDrugs; 2001; 15(5):325-37. PubMed ID: 11437695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroinflammatory perspectives on the two faces of Alzheimer's disease.
    Eikelenboom P; van Gool WA
    J Neural Transm (Vienna); 2004 Mar; 111(3):281-94. PubMed ID: 14991455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence.
    Eikelenboom P; Veerhuis R; van Exel E; Hoozemans JJ; Rozemuller AJ; van Gool WA
    Curr Alzheimer Res; 2011 Mar; 8(2):142-50. PubMed ID: 21345167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications.
    Hoozemans JJ; Veerhuis R; Rozemuller AJ; Eikelenboom P
    Drugs Today (Barc); 2002 Jun; 38(6):429-43. PubMed ID: 12532179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammation in Alzheimer's disease and prion disease.
    Eikelenboom P; Bate C; Van Gool WA; Hoozemans JJM; Rozemuller JM; Veerhuis R; Williams A
    Glia; 2002 Nov; 40(2):232-239. PubMed ID: 12379910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pro-inflammatory cytokines in Alzheimer's disease].
    Stamouli EC; Politis AM
    Psychiatriki; 2016; 27(4):264-275. PubMed ID: 28114090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation.
    Regen F; Hellmann-Regen J; Costantini E; Reale M
    Curr Alzheimer Res; 2017; 14(11):1140-1148. PubMed ID: 28164764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.
    McGeer PL; McGeer EG
    Acta Neuropathol; 2013 Oct; 126(4):479-97. PubMed ID: 24052108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukins, inflammation, and mechanisms of Alzheimer's disease.
    Weisman D; Hakimian E; Ho GJ
    Vitam Horm; 2006; 74():505-30. PubMed ID: 17027528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglia as a potential bridge between the amyloid beta-peptide and tau.
    Kitazawa M; Yamasaki TR; LaFerla FM
    Ann N Y Acad Sci; 2004 Dec; 1035():85-103. PubMed ID: 15681802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b.
    Huang W; Li Z; Zhao L; Zhao W
    Biomed Pharmacother; 2017 Aug; 92():46-57. PubMed ID: 28528185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease.
    McDonald CL; Hennessy E; Rubio-Araiz A; Keogh B; McCormack W; McGuirk P; Reilly M; Lynch MA
    Brain Behav Immun; 2016 Nov; 58():191-200. PubMed ID: 27422717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.
    Haure-Mirande JV; Audrain M; Fanutza T; Kim SH; Klein WL; Glabe C; Readhead B; Dudley JT; Blitzer RD; Wang M; Zhang B; Schadt EE; Gandy S; Ehrlich ME
    Acta Neuropathol; 2017 Nov; 134(5):769-788. PubMed ID: 28612290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling.
    Zheng JY; Sun J; Ji CM; Shen L; Chen ZJ; Xie P; Sun YZ; Yu RT
    Neurobiol Aging; 2017 Jun; 54():112-132. PubMed ID: 28366226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
    Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
    J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model.
    Kim DG; Krenz A; Toussaint LE; Maurer KJ; Robinson SA; Yan A; Torres L; Bynoe MS
    J Neuroinflammation; 2016 Jan; 13():1. PubMed ID: 26728181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.